课题基金 / 基金详情

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease
阿司匹林加剧的呼吸系统疾病的治疗控制
批准号:
8195751
负责人:
Elliot Israel
金额:
$48.48万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-15 至 2016-06-30

项目摘要

项目成果

Elliot Israel的其他基金

相似基金

相关文献

中文摘要
翻译
阿司匹林加重呼吸系统疾病(AERD)的特征是严重的鼻窦炎和鼻息肉。
英文摘要
Aspirin exacerbated respiratory disese (AERD) is characterized by severe rhinosinusitis and nasal polposis, as well as asthma that is often severe. We and others have previously demonstrated that the pathophysiology of AERD involves a marked contribution from the 5-lipoxygenase (5-LO) pathway, particularly the cysteinyl leukotrienes and their stable end-product, leukotriene (LT)E4. Our colleagues in Project 1 have found that EP2 receptors are markedly deficient on platelets and leukocytes from individuals with AERD, resulting in markedly increased circulating platelet-leukocyte aggregates (a potential source of LTC4 that gives rise to LTE4). In this Project, we propose a proof-of-principle, double-blind, placebocontrolled crossover trial of prasugrel (a widely used P2Y12 receptor antagonist) in AERD to test the hypothesis that P2Y12 receptors, due to their role in platelet activation in general and LTE4-mediated pulmonary inflammation in particular, are viable therapeutic targets in AERD. In addition, we have shown with our colleagues in Project 1 that leukocytes from individuals with AERD express markedly lower levels of COX-2 mRNA and protein, and generate less COX-2-dependent PGE2 relative to leukocytes from nonasthmatic and aspirin tolerant asthmatic (ATA) control subjects. Desensitization followed by treatment with aspirin for 2 months restores both COX-2 expression and COX-2-dependent PGE2 production on a cellular level, while abrogating the cellular generation of thromboxane A2. In Aim 2 of this project, we will use an intervention with aspirin desensitiztion determine the molecular basis for COX-2 defciency and to test the hypothesis that a deficiency in COX-2-derived PGE2 accounts for aspirin intolerance in AERD, and that restoring COX-2 function is a mechanism for the efficacy treatment with aspirin after desensitization. These mechanistic intervention studies are urgently needed to develop improved treatment and identify causal mechanisms for AERD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 3: Therapeutic Control of AERD
  • 批准号:
    10208132
  • 项目类别:
  • 资助金额:
    $11.42万
  • 财政年份:
    2020
  • 负责人:
    Elliot Israel
  • 依托单位:
PATINA - Precision Administration of Treatment in Neutrophilic severe Asthma
  • 批准号:
    9406614
  • 项目类别:
  • 资助金额:
    $42.1万
  • 财政年份:
    2017
  • 负责人:
    Elliot Israel
  • 依托单位:
PATINA - Precision Administration of Treatment in Neutrophilic severe Asthma
  • 批准号:
    10454802
  • 项目类别:
  • 资助金额:
    $43.43万
  • 财政年份:
    2017
  • 负责人:
    Elliot Israel
  • 依托单位:
PATINA - Precision Administration of Treatment in Neutrophilic severe Asthma
  • 批准号:
    9751385
  • 项目类别:
  • 资助金额:
    $48.19万
  • 财政年份:
    2017
  • 负责人:
    Elliot Israel
  • 依托单位:
海外基金